West Announces Third-Quarter 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
West Pharma (WST) Tops Q3 EPS by 16c, Revenues Beat; Raises FY20 EPS/Revenue Guidance Above Consensus
October 22, 2020 6:11 AM EDTWest Pharma (NYSE: WST) reported Q3 EPS of $1.15, $0.16 better than the analyst estimate of $0.99. Revenue for the quarter came in at $548 million versus the consensus estimate of $510.14 million.
Third-Quarter 2020 Summary (comparisons to prior-year period)
Net sales of $548.0 million grew 20.1%; organic sales growth was 18.2%.Reported-diluted EPS of $1.09 increased 45%.Adjusted-diluted EPS of $1.15 increased 46%.Company is raising full-year 2020 net sales guidance to a new range of $2.10 billion and $2.11 billion.Company is raising full-year 2020 adjusted-diluted EPS guidance to a new range of $4.50 and $4.55."Adjusted-diluted EPS" and "organic sales... More
